Posts

Sanofi halts eczema development of Kymab-originated OX40L antibody amlitelimab due to lack of meaningful clinical advantage and safety concerns

on
Sanofi has discontinued clinical development of amlitelimab (an OX40L-targeting antibody originating from Kymab) in moderate-to-severe atopic dermatitis and will not seek regulatory approval for the drug in eczema. The decision follows a strategic pipeline review in which Sanofi concluded that the overall efficacy and safety data, including emerging safety signals such as Kaposi’s sarcoma, do not support a meaningful improvement over existing standard-of-care therapies. Amlitelimab, acquired with Kymab in a $1.1 billion deal in 2021, generated positive Phase 2 and Phase 3 results but failed to justify continued development amid safety concerns and a crowded AD treatment landscape. Sources: Sanofi won't seek approval for eczema drug from Kymab ... Your Weekly Biotech News Fix | Ep. 1041 - BowTiedBiotech Sanofi abandons amlitelimab in atopic dermatitis despite pos Sanofi to Acquire Kymab, Adding KY1005 to Pipeline JPM: Sanofi inks $1.1B Kymab buyout to bag midphase .....

FDA Adcomm Backs Popular Wellness Peptides Despite Staff Concerns

on

AstraZeneca’s pipeline struggles continue with disappointing late-stage cancer and rare disease data

on

Summit Touts Updated HARMONi Data Showing Consistent Survival Benefit for Ivonescimab in Western NSCLC Patients

on

Bylvay Fails Phase 3 BOLD Trial in Biliary Atresia, Another Setback for Ipsen's Albireo Portfolio

on

Amgen Submits Extensive Data Package to FDA in Defense of Tavneos Approval

on

Emideltide narrowly voted down by FDA peptide advisory panel on Day 2

on

Biogen's Tau-Targeting Alzheimer's Drug Shows Promising but Confusing Results

on

Roche sees receding biosimilar impact, but Vabysmo slump returns

on

Scancell merges with Neuphoria after Merck axes trial

on

Gene editor Scribe Therapeutics starts second-half IPO spree with $129M listing

on

BeOne boosts US footprint with $300M New Jersey expansion

on

FDA Clears Momentis Surgical's Anovo System for Multiport Surgery, Making It the First Robotic Platform to Support Three Surgical Approaches

on